ISK Trademark

Trademark Overview


On Tuesday, February 2, 2016, a trademark application was filed for ISK with the United States Patent and Trademark Office. The USPTO has given the ISK trademark a serial number of 79186613. The federal status of this trademark filing is SECTION 71 ACCEPTED as of Friday, March 22, 2024. This trademark is owned by ISHIHARA SANGYO KAISHA, LTD.. The ISK trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of Anti-inflammatory, [ anti-shock, ] inflammation of digestive system, [ inflammation of respiratory system, ] anti-pancreatitis, [ pulmonary insufficiency, kidney disease, disseminated intravascular coagulation, chronic obstructive pulmonary disease, pyometra, spondylosis deformans, systemic inflammatory response syndrome, pneumonia, infectious peritonitis, sepsis, inhibiting thrombogenesis, allergy, tumor metastasis control, infectious disease, encephalitis and surgical stress; ] veterinary preparations for Companion animals, farm animals, dogs [, cats, horses, chickens, cattle and pigs ] for the treatment of Anti-inflammatory, [ anti-shock, ] inflammation of digestive system, [ inflammation of respiratory system, ] anti-pancreatitis, [ pulmonary insufficiency, kidney disease, disseminated intravascular coagulation, chronic obstructive pulmonary disease, pyometra, spondylosis deformans, systemic inflammatory response syndrome, pneumonia,...
isk

General Information


Serial Number79186613
Word MarkISK
Filing DateTuesday, February 2, 2016
Status706 - SECTION 71 ACCEPTED
Status DateFriday, March 22, 2024
Registration Number5173581
Registration DateTuesday, April 4, 2017
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, January 17, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of Anti-inflammatory, [ anti-shock, ] inflammation of digestive system, [ inflammation of respiratory system, ] anti-pancreatitis, [ pulmonary insufficiency, kidney disease, disseminated intravascular coagulation, chronic obstructive pulmonary disease, pyometra, spondylosis deformans, systemic inflammatory response syndrome, pneumonia, infectious peritonitis, sepsis, inhibiting thrombogenesis, allergy, tumor metastasis control, infectious disease, encephalitis and surgical stress; ] veterinary preparations for Companion animals, farm animals, dogs [, cats, horses, chickens, cattle and pigs ] for the treatment of Anti-inflammatory, [ anti-shock, ] inflammation of digestive system, [ inflammation of respiratory system, ] anti-pancreatitis, [ pulmonary insufficiency, kidney disease, disseminated intravascular coagulation, chronic obstructive pulmonary disease, pyometra, spondylosis deformans, systemic inflammatory response syndrome, pneumonia, infectious peritonitis, sepsis, inhibiting thrombogenesis, allergy, tumor metastasis control, infectious disease, encephalitis and surgical stress; ] pharameutical agents affecting digestive organs; [ pharmaceutical preparations for skin care for animals; pharmaceutical [ preparations and ] agents, namely, medical test kits composed primarily of reagents and vectors; veterinary preparations and agents, namely, medical test kits composed primarily of reagents and vectors; pharmaceutical preparations and agents, namely, surgical or orthopedic bone cement and medical bone bonding agent; veterinary preparations and agents, namely, surgical or orthopedic bone cement and medical bone bonding agent; ] medicines for veterinary purposes for Companion animals, farm animals, dogs [, cats, horses, chickens, cattle and pigs ] for the treatment of Anti-inflammatory, [ anti-shock, ] inflammation of digestive system, [ inflammation of respiratory system, ] anti-pancreatitis [, pulmonary insufficiency, kidney disease, disseminated intravascular coagulation, chronic obstructive pulmonary disease, pyometra, spondylosis deformans, systemic inflammatory response syndrome, pneumonia, infectious peritonitis, sepsis, inhibiting thrombogenesis, allergy, tumor metastasis control, infectious disease, encephalitis and surgical stress ]
Pseudo MarkISHIHARA SANGYO KAISHA
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 10, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameISHIHARA SANGYO KAISHA, LTD.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressOsaka 550-0002
JP

Party NameISHIHARA SANGYO KAISHA, LTD.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressOsaka 550-0002
JP

Party NameISHIHARA SANGYO KAISHA, LTD.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressOsaka 550-0002
JP

Trademark Events


Event DateEvent Description
Saturday, May 14, 2016APPLICATION FILING RECEIPT MAILED
Thursday, May 5, 2016SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Monday, May 9, 2016LIMITATION FROM ORIGINAL APPLICATION ENTERED
Tuesday, May 10, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, May 15, 2016ASSIGNED TO EXAMINER
Friday, May 20, 2016NON-FINAL ACTION WRITTEN
Saturday, May 21, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, May 23, 2016REFUSAL PROCESSED BY MPU
Monday, May 23, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, June 10, 2016REFUSAL PROCESSED BY IB
Friday, November 18, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 7, 2016ASSIGNED TO LIE
Saturday, December 10, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, December 10, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, December 10, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, December 15, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, December 28, 2016NOTICE OF PUBLICATION
Wednesday, December 28, 2016NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, December 28, 2016NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Thursday, January 12, 2017NOTIFICATION PROCESSED BY IB
Tuesday, January 17, 2017PUBLISHED FOR OPPOSITION
Thursday, March 16, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 4, 2017REGISTERED-PRINCIPAL REGISTER
Tuesday, July 4, 2017FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, July 14, 2017FINAL DISPOSITION PROCESSED
Friday, July 14, 2017FINAL DISPOSITION NOTICE SENT TO IB
Friday, August 4, 2017FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, April 4, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, June 17, 2022INTERNATIONAL REGISTRATION RENEWED
Wednesday, March 15, 2023TEAS SECTION 71 RECEIVED
Thursday, October 5, 2023CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, October 10, 2023POST REGISTRATION ACTION MAILED - SEC.71
Thursday, February 22, 2024TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Friday, March 22, 2024REGISTERED-SEC.71 ACCEPTED
Friday, March 22, 2024NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Tuesday, July 23, 2024PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Tuesday, July 23, 2024INVALIDATION PROCESSED
Friday, June 14, 2024PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED